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Phenacetin and papillary necrosis: independent risk factors for renal
pelvic cancer. A case—control study was undertaken to determine
whether renal papillary necrosis (RPN) is an essential step in thc
genesis of analgcsic—associated canccr of the renal pelvis (CaP). Kid-
neys of 66 patients (and 86 cases of renal parenchymal cancer (CaK),
for comparison) were examined for evidence of RPN. Information
concerning past consumption of phenacetin—containing analgesics(PhA) was obtained from all cases and 751 population controls by
means of a questionnaire. Separately, RPN and regular consumption of
PhA each conferred a relative risk for CaP of 3-1/2 to 7, while together
they increased the risk some 20 times that for non-consumers without
RPN. This suggests that each factor has independent, and when they
coexist sequential, effects. The risk for CaK was doubled by regular
PhA consumption but was not increased by RPN.
Although renal papillary necrosis (RPN) has been found in a
high proportion of subjects with analgesic—associated cancer of
the renal pelvis (CaP), there is no agreement as to whether RPN
is an essential step in the genesis of this cancer. Those who
believe that phenacetin itself is a chemical carcinogen, gener-
ally have postulated that those tissue changes which precede
transitional—cell carcinoma occur separately from, and parallel
to, phenacetin's nephrotoxic effect which results in RPN [11.
Thus can he explained the production of urothelial tumors,
apparently without co-existing RPN, by feeding phenacetin to
rats [2], a species which is resistant to the nephrotoxic effects of
this drug [3].
On the other hand, by analogy with transitional—cell tumors
which arise in association with chronic urological disease, it has
been proposed that RPN, which frequently is associated with
urinary obstruction and infection, is an intermediate stage in the
development of CaP. In support of this is the observation that in
patients who have taken analgesics, CaP has been reported
infrequently in the absence of RPN. Indeed, RPN has been
found in 75% of the 124 well—documented case reports of
analgesic—associated CaP published up to, and including, 1973
14] and in 92, 87 and 57%, respectively, of one Swedish and two
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Australian series of such cases published between 1974 and
1979 [5—7].
To elucidate whether the presence of RPN is a necessary
intermediate stage in the development of analgesic—associated
CaP, a retrospective case—control study was undertaken to
determine the relative risk associated with the presence of RPN
alone, the consumption of phenacetin—containing analgesics
(PhA) alone, or the occurrence of both risk factors together.
Information was obtained from patients with CaP concerning
their past consumption of analgesics, and the kidneys from
these patients were examined for evidence of RPN. A compar-
ison was made with patients with adenocarcinoma of the kidney
(CaK).
St
Methods
All adult eases of primary kidney cancer admitted to five
major teaching hospitals in Sydney between January 1977 and
September 1982, and a sixth teaching hospital between January
1970 and September 1982 were included if surgical specimens
were available for examination. One of two pathologists (JJC
and JT) classified the tumors according to their histological
appearances as arising from the renal pelvis (including both
transitional—cell and squamous—cell carcinomas; lCD, 8th revi-
sion, 189.1) or kidney (adenocarcinomas; lCD 189.0), and
sought evidence of 'intermediate' or 'advanced' RPN, accord-
ing to Burry [8], without prior knowledge of the analgesic
history. Cases were excluded if the presence or absence of RPN
could not be established, because either the section submitted
did not show papilla or the papillary architecture was obscured
by the tumor. A history of analgesic consumption was obtained
through completion of a structured questionnaire at interview
91 by MMcC or JHS, who at the time were unaware of the
histopathological findings. So included were 66 eases of CaP (44
female, 22 male) and 86 eases of CaK (27 female, 59 male).
For the estimation of relative risk, data were included from a
control group comprising 444 female (aged 45 to 84 yr) and 3(17
male (50 to 89 yr) respondents from a systematic random
sample of the adult population of New South Wales, obtained
by taking every thousandth name from the electoral rolls 110,
111.
The total amount consumed of phenacetin—containing anal-
gesics was calculated using the frequency and duration of
consumption recorded in the questionnaire, together with the
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Table 1. Risk ratios for renal cancer according to (a) regular consumption of phenacetin-containing analgesics (PhA) and (b) renal papillary
necrosis (RPN)
Cancer of the
renal pelvis
Cancer of the
renal parenchyma
Population
controls"
F M F M F M
N 44 22 27 59 444 307
Agemean±sD 61±9 62± 9 61±13 61± 10 60±9 62±8
PhA +, RPN b 23 4 1 0 31 4
PhA +, RPN — 5 2 3 10 22 22
PhA—,RPN+ 2 1 0 1 9 2
PhA —, RPN — 14 15 23 48 382 279
Risk ratios"
Associated with PhA
—RPN absent
—RPN present
3.6 (16_81)d
20 (12—34)"
2.5 (1.3_4.9)"
0.4 (0.1—2.7)
Associated with RPN
—PhA absent 6.9 (2.1—22)" 1.1 (0.1—9.6)
a Population controls were distributed according to estimates of RPN in the Brisbane population (9% in women, 2% in men) [16, 17] and the
relative risk for RPN associated with PhA of 27 [18]b + = present; — absent
Mantel—Haenszel estimates (adjusted for sex) with 95% confidence limitsd 99% confidence limits also lay entirely above 1.0
known composition of various analgesic preparations. A life-
time total of at least 1 kg (that is, about four powders or tablets
a day for one year of preparations containing aspirin,
phenacetin and either caffeine or codeine) was considered to
represent 'regular', and less than this amount 'never regular',
consumption.
Statistical analysis
Relative risks (RR) were calculated according to the
Mantel—Haenszel formula 12]:
RR = (a/b) / (c/d)
where a = number of cases exposed to the risk factor,
b = number of cases not exposed,
c = number of controls exposed,
d = number of controls not exposed.
For each of the two risk factors examined, stratification was
employed to take into account the presence or absence of the
other, and the sex of the subject. The relative risks together
with Miettinen's test—based confidence limits [13] were com-
puted as described by Breslow and Day [14] using calculator
programs devised by Rothman and Boice [15].
Results
The age at diagnosis (for cases) or interview (for controls)
was similar in the three groups 1). The distribution of
cases with renal pelvic (CaP) or parenchymal (CaK) cancer and
population controls is given according to whether each had (a)
renal papillary necrosis (RPN) and (b) taken phenace-
tin—containing analgesics (PhA) regularly.
From Table 1, it can be calculated that the prevalence of RPN
among analgesic takers with CaP with 79% (27 out of 34) while
the corresponding figure for CaK was 7% (1 out of 14). This
difference could not readily be explained by the amount or
duration of PhA consumption (Table 2).
Table 2. Consumption of phenacetin—containing analgesics by
subjects with cancer of the renal pelvis or renal parenchyma
Phenacetin—containing analgesics
Cancer of the renal pelvis
No. of
consumers
Amount
consumed
kg
Duration of
consumption
yr
RPN —present (N = 30) 27 24 17 29 16
absent (N = 36) 7 19 17 22 17
Cancer of the renal parenchyma
RPN — present (N = 2) 1 27 24
— absent (N 84) 13 13 14 21 14
Controls
(N = 751) 79 14 19 16 11
a RPN = renal papillary necrosis
As it was not possible to determine directly whether or not
RPN was present in the population controls, this group was
partitioned (Table 1) according to (i) PhA consumption as
recorded in the questionnaire, (ii) a prevalence of RPN for the
whole control group of 9% for women, and 2% for men, as
determined from two Brisbane autopsy surveys [16, 171 and (iii)
a relative risk for RPN of 27 in those who had consumed at least
1 kg of PhA when compared with those consuming less than this
amount, This relative risk of 27 was calculated for the New
South Wales population from data previously published [181,
but reanalyzed using the level of analgesic consumption set for
this study.
In the absence of the other risk factor, RPN increased the
relative risk for CaP some sevenfold while PhA consumption
increased the risk by a factor of about 3-1/2. When both were
present, however, the risk was increased to 20 times that for
persons exposed to neither risk factor (Table 1).
The relative risk for CaK was doubled by the consumption of
PhA, but was not increased by the presence of RPN. Indeed, as
the prevalence of RPN among cases with CaK was less than
that estimated for the control group, the presence of RPN
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appeared to decrease the risk for analgesic—associated CaK
(Table 1).
Discussion
In order to calculate risk ratios for cancer of the kidney
associated with the presence of renal papillary necrosis (RPN),
the frequency of RPN must be known in the control group as
well as in the cancer groups. Because the diagnosis of RPN can
be made only by pathological examination of the kidney or, less
certainly, by pyelography, neither of which could be contem-
plated in the population control group, we were obliged to use
an indirect estimate of the occurrence of RPN in these subjects.
The only autopsy surveys performed in Sydney have been in
patients dying in teaching hospitals [19, 20], a category known
to have a higher prevalence of RPN than the population—at—
large [16, 17]. Therefore, we have used figures relating to two
series of coroner's autopsies in another large Australian city,
Brisbane [16, 171. This was felt to be justified as the frequencies
of RPN in the hospital autopsy studies in Brisbane and Sydney
were similar and the Brisbane population has consumed
phenacetin—containing analgesics (PhA) at about the same rate
as Sydney residents [21, 22]. The female:male ratios of 4.5:1 in
the prevalence of RPN in the Brisbane coroner's surveys
accords with that of two series of Sydney cases of RPN (5:1
[23]; 7:1 [181).
Given that this estimate of the prevalence of RPN in the
population is accurate, our results indicate that both RPN and
regular PhA consumption are independent risk factors for renal
pelvic cancer (CaP), increasing the risk by a factor of about 7
and 3-1/2 respectively.
Were the Brisbane figures to be an overestimate of the
prevalence of RPN in the NSW population, as suggested by the
frequency of RPN in our cases with CaK (4% in women, 2% in
men), the case for RPN having a carcinogenic role in the
development of CaP would be strengthened. However, as the
median age of the Brisbane cases lies between 55 and 60 in both
sexes (that is, about five years younger than in our patients)
then, because the frequency of RPN increases with age, the
prevalence that we have used may be an underestimate. Be-
cause of this, we have calculated what the relative risk would be
were the true prevalence in the population—at—large 1-1/2 times
that used for the calculations given in Table 1. The relative risks
then would be 5 for RPN alone, 6 for PhA consumption alone
and 13 for the presence of both factors together.
All our cancer cases were from large teaching hospitals to
which cases with RPN may have been preferentially referred
because of associated urinary obstruction or infection, renal
failure, or hypertension. While this may have been a source of
selection bias, the proportion of analgesic—associated pelvic
tumors found with coexisting RPN in this series, 79%, is within
the range recorded in previously published studies [4—7].
If the nephrotoxic and carcinogenic effects of phenace-
tin—containing analgesics occurred separately, the risk for CaP
associated with PhA consumption would be unaltered by the
presence or absence of RPN. Clearly the data examined here
deny this possibility, for the risk among patients exposed to
PhA was more than five times greater in the presence of RPN
than in its absence. Indeed, the Mantel—Haenszel risk ratios
(stratified for sex) indicated that RPN and PhA consumption
each had non-chance associations with CaP in the absence of
the other factor; and, when both factors were present, the risk
increased in a multiplicative fashion. This suggests that PhA
and RPN have independent, and when they coexist sequential,
effects.
Could the presence of RPN in cancer—bearing kidneys merely
reflect the fact that in the course of evolution of PhA-induced
renal disease, the nephrotoxic effect (RPN) appears before the
carcinogenic effect (CaP)? Certainly RPN is more common than
CaP, but in previous investigations [9—11, 18], there was no
difference in either the quantity, or the duration of PhA con-
sumption leading to each of the two diseases. Moreover, the
data in Table 2 show that the amount of PhA consumed by the
cancer patients was only moderately (and not significantly)
higher in those with RPN than in those without. It is also clear
from this table that RPN is by no means an invariable conse-
quence of heavy PhA consumption. Given the present obser-
vations and those already published, it does appear that there is
a closer association between RPN and CaP than can be ex-
plained purely on the basis of the two diseases being caused by
heavy exposure to the same agent.
Previous studies have shown that CaP and RPN are both
associated with analgesics that contain phenacetin (mainly
powders or tablets of aspirin, phenacetin and caffeine or co-
deine) but not with those which contain no phenacetin (mainly
aspirin and/or paracetamol with or without other ingredients)
[9—il]. An examination of the primary data from the case—
control studies reported in references 9 to 11 and 18 showed no
association of paracetamol—containing analgesic consumption
with cancer of the kidney or renal pelvis or with RPN, when the
effect of exposure to phenacetin was taken into account in the
calculation. Moreover, there is no experimental evidence im-
plicating paracetamol with cancer at these sites. Phenacetin's
carcinogenic effect is thought to result from the potent
alkylating action of the N-O-sulphate and -glucuronide conju-
gates of N-hydroxy-phenacetin [24]. However, the chief metab-
olite of phenacetin, paracetomol, probably does not undergo
N-hydroxlation [251.
That regular PhA consumption appears to double the risk for
cancer of the kidney (CaK) in this series is in keeping with the
findings of a case—control study from Minneapolis, which
demonstrated a relative risk for CaK of 2.2 for men and 2.5 for
women associated with prolonged use of this type of analgesic
[26]. However, unlike the situation in CaP, there is no body of
clinical evidence linking RPN with CaK, nor did our results
suggest that such an association was likely. Thus, the relation-
ship between consumption of phenacetin—containing analgesics
and CaK appears to be entirely a direct one without any
intervening effect of RPN.
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